Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit

Zynerba Pharmaceuticals

DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced that Stephen O’Quinn, Vice President, Medical Affairs, Zynerba Pharmaceuticals, will participate in a panel discussion at the 2022 Cantor Rare Orphan Disease Summit taking place virtually March 29-30, 2022.

Panel Details

Title: Rare Neurodevelopmental Disorders
Date: Wednesday, March 30, 2022
Time: 11:00 a.m. – 12:15 p.m. ET

If you have an interest in participating in the Cantor Virtual Rare Orphan Disease Summit, please reach out to your Cantor Fitzgerald representative.

Zynerba Pharmaceuticals is a developer of pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.

READ:  NeuExcell Therapeutics, Inc. to Present at the UBS Biotechnology Virtual Private Company Symposium